medigraphic.com

2007, Número 2

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2007; 45 (2)


Cáncer de mama. Detección oportuna en el primer nivel de atención

Torres-Arreola LP, Vladislavovna DS

Idioma: Español
Referencias bibliográficas: 62
Paginas: 157-166
Archivo PDF: 81.81 Kb.


RESUMEN

El aumento constante de la morbilidad y mortalidad por cáncer de mama durante las últimas décadas, ha llevado a estudiar más los métodos de detección oportuna y cómo han contribuido a disminuir la mortalidad por esta enfermedad. Se realizó una búsqueda en Ovid-Medline, Cochrane, Synergy, Medic Latina, Science Direct, Ebsco-e-Journal Services, de la bibliografía relativa al tema publicada entre 1980 y 2005. La revisión se enfocó en el panorama epidemiológico del cáncer de mama, los factores de riesgo y los métodos de detección (beneficios y limitaciones), con el propósito de actualizar al médico de primer nivel en los avances diagnósticos más eficientes y útiles en la detección oportuna del cáncer de mama.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Secretaría de Salud. Información para la rendición de cuentas. Salud México 2002. México: SSa; 2003.

  2. Collyar DE. Breast cancer: a global perspective. J Clin Oncol 2001;19:101-105.

  3. Secretaría de Salud. Tratamiento gratuito para personas que padecen cáncer de mama. Comunicado de prensa 058. México: SSa; 2005. Disponible en http://www.salud.gob.mx/ssa_app/noticias/datos/2005-02-12_1207.html

  4. Secretaría de Salud. Registro histopatológico de neoplasias malignas. México: Dirección General de Epidemiología, SSa; 2001.

  5. López-Ríos O, Lascano-Ponce EC, Tovar-Guzmán V, Hernández-Ávila M. La epidemia de cáncer de mama en México. ¿Consecuencia de la transición demográfica? Salud Publica Mex 1997;39(4):259-265.

  6. Gómez-Dantés H, Vázquez-Martínez JL, Fernández-Cantón S. Detección de cáncer de mama en las mujeres derechohabientes del IMSS. Resultados de la Encuesta Nacional de Salud 2000. Documento técnico. Dirección de Prestaciones Médicas. México: IMSS; 2003. Disponible en http://www.imss.gob.mx/dpm/dties//DTIES. aspx?Ser=SRV01&OPC=opc06&

  7. Proyecciones de la población de México, 2000 a 2050. México: INEGI-SSa-CONAPO; 2002. Disponible en http://www.emexico.gob.mx/wb2/eMex/eMex_Proyecciones_de_la_ poblacion_de_Mexico_200020

  8. Instituto Nacional de Estadística, Geografía e Informática. 4 de febrero, Día Mundial contra el Cáncer. México: INEGI; 2005. Disponible en http://www.dif.gob.mx/inegi/DiaMundialcontraCancer.pdf

  9. Rodríguez-Cuevas S, Macías-Martínez CG, Labastida-Almendaro S. Breast cancer in Mexico. Is it a young women disease? Ginecol Obstet Mex 2000;68:185-190.

  10. Secretaría de Salud. Compendio del Registro Histopatológico de Neoplasias Malignas en México. Morbilidad. Regionalización 1993-1996 y mortalidad, años de vida potencialmente perdidos, 1985-1995. México: Dirección General de Epidemiología, SSa; 1998.

  11. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas 2001;38:103-113.

  12. Clamp A, Danson S, Clemons M. Hormonal risk factors for breast cancer: identification, chemoprevention and other intervention strategies. Lancet Oncol 2002;3:611-619.

  13. National Cancer Institute. Surveillance, epidemiology and end results program, 1995-1997. Disponible en http://www.nci.noh.gov

  14. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-1059.

  15. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiologycal studies. Lancet 1996;347:1713-1727.

  16. Collaborative Groups on Hormonal Factors in Breast Cancer. Familial breast cancer collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without breast cancer. Lancet 2001;358:1389-1399.

  17. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000;321:624-628.

  18. Dumitrescu RG, Cotarla L. Understanding breast cancer risk- where do we stand in 2005? J Cell Mol Med 2005;9:208-221.

  19. Beral V. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease. Lancet 2002; 360:187-195.

  20. Bloom JR. Early detection of cancer. Psychological and social dimensions. Cancer 1994;74 Suppl 4:1464-1473.

  21. Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G et al. Breast carcinoma survival in Europe and the United States. Cancer 2004;100(4):715-722.

  22. Jatoi I. Breast cancer screening. Am J Surg 1999;177:518-524.

  23. Humphrey LL, Chan BKS, Deglefsen S, Helfand M. Screening for breast cancer. Systematic Evidence Review 15. Disponible en http://www.ahrq.gov/clinic/serfiles.htm

  24. Baxter N. Preventive health care, 2001 update: Should women be routinely taught breast self-examination to screen for breast cancer? CMAJ 2001;164(13):1837-1846.

  25. Pinto B, Fugua WR. Training breast self examination: a research review and critique. Health Educ Q 1991;18:495-516.

  26. Assaf A, Cummings MK, Graham S, Mettin C, Marshal I. Comparison of three methods of teaching women how to perform breast self examination. Health Educ Q 1985;12:259-272.

  27. Ortega-Altamirano D, López-Carillo L, López-Cervantes M. Estrategias para la enseñanza del autoexamen del seno a mujeres en edad reproductiva. Salud Publica Mex 2000;42:17-25.

  28. McDonald S, Saslow D, Alciati MH. Performance and reporting of clinical breast examination: a review of the literature. CA Cancer J Clin 2004;54:345-361.

  29. Bancej C, Decker K, Chiarelli A, Harrison M, Turner D, Brisson J. Contribution of clinical breast examination to mammography screening in the early detection of breast cancer. J Med Screen 2003;10:16-21.

  30. Fletcher SW, O’Malley MS, Bunce LA. Physicians abilities to detect lumps in silicone breast models. JAMA 1985;253:2224-2228.

  31. Barton MB, Harris R, Fletcher SW. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA 1999;282(13):1270-1280.

  32. Bobo JK, Lee NC, Thames SF. Findings from 752 081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 2000; 92:971-976.

  33. Hall DC, Adams CK, Stein GH, Stephenson HS, Goldstein MK, Pennypacker HS. Improved detection of human breast lesions following experimental training. Cancer 1980; 46:408-414.

  34. Meissner HI, Breen N, Yabroff KR. Whatever happened to clinical breast examinations? Am J Prev Med 2003;25:259-263.

  35. Kim CS, Kristopaitis RJ, Stone E, Pelter M, Sandhu M, Weingarten SR. Physician education and report cards: do they make the grade? Results from a randomized controlled trial. Am J Med 1999;107:556-560.

  36. Lane DS, Messina CR. Current perspectives on physician barriers to breast cancer screening. J Am Board Fam Pract 1999;12:8-15.

  37. Keller B, Zemp SE, Tiblin M, Ackermann-Liebrich U, Faisst K, Probs-Hensch N. Screening mammographies in Switzerland: what makes female and male physicians prescribe them? Swiss Med Wkly 2001;131:311-319.

  38. Lane DS, Caplan LS, Grimson R. Trends in mammography use and their relation to physician and other factors. Cancer Detect Prev 1996;20:332-341.

  39. Poblano-Verástegui O, Figueroa-Perea JG, López-Carillo L. Condicionantes institucionales que influyen en la utilización del examen clínico de mama. Salud Publica Mex 2004; 46:294-305.

  40. Saslow D, Hannan J, Osuch J, Alciati MH, Baines C, Barton M et al. Clinical breast examination: practical recommendations for optimizing performance and reporting. CA Cancer J Clin 2004;54(6):327-344.

  41. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten to fourteen-year effect of screening on breast cancer mortality. JNCI 1982;69:349-355.

  42. World Health Organization. International Agency for Research on Cancer. IARC handbooks of cancer prevention: breast cancer screening. Lyon: IARC Press; 2002.

  43. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammografy service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003;361(9367):1405-1410.

  44. Duffy SW, Tabar L, Smith RA. The mammografic screening trials: commentary on the recent work by Olsen and Gotzsche. CA Cancer J Clin 2002;52-68-71.

  45. National Institutes of Health Consensus Development Program. Breast cancer screening for women ages 40-49. 1997. Disponible en http://consensus.nih.gov/1997/1997BreastCancer Screening103PDF.pdf

  46. Borrás JM, Espinás JA, Castells X. La evidencia del cribado del cáncer de mama: la historia continúa. Gac Sanit 2003;17(3):249-255.

  47. Miller AB, To Teresa, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. Ann Intern Med 2002; 137:305-312.

  48. Retsky M, Demicheli R, Hrushesky W. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat 2001;65(3):217-224.

  49. Naumov GN, MacDonald IC, Weinmeister PM, Kerkvliet N, Nadkarni KV, Wilson SM, Morris VL, Groom AC, Chambers AF. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002;62:2162-2168.

  50. Bjurstam N, Bjorneld L, Duffy SW, Smith TC, Cahlin E, Erikson O, Lingaas H, Mattsson J, Persson S, Rudenstam CM, Sawe-Soderberg J. The Gothenburg Breast Cancer Screening Trial: Preliminary results on breast cancer mortality for women aged 39-49. J Natl Cancer Inst Monogr 1997;22:53-55.

  51. Humphrey LL, Helfand M, Chan B, Woolf SH. Breast cancer screening: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:347-360.

  52. U.S. Preventive Task Force. Screening for breast cancer. Recommendations and rationale. 2002. Disponible en http://www.ahrq.gov/clinic/3rduspstf/breastcancer/brcanrr.pdf

  53. Law J, Faulkner K. Cancers detected and induced, and associated risk and benefit, in a breast screening programme. Br J Radiol 2001; 74:1121-1127.

  54. Law J, Faulker K. Concerning the relationship between benefit and radiation risk, and cancers detected and induced, in a breast screening programme. Br J Radiol 2002;75:678-684.

  55. Barrat AL, Les Irwig M, Glasziou PP, Salkeld GP, Houssami N. Benefits harms and costs of screening mamography in women 70 years and over: a systematic review. Med J Aust 2002;176:266-271.

  56. Kerlikowske K., Grady D, Barclay J, Sickles E, Ernster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 1996;276:33-38.

  57. Humphrey LL, Helfand M, Chan BKS. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:347-360.

  58. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast U. S. and evaluation of factors that influence them: an analysis of 27 825 patient evaluations. Radiology 2002;225:165-175.

  59. Elmore JG, Barton MB, Mocceri VM. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998;338(16):1089-1096.

  60. Mushlin AI, Kouides RW, Shapiro DE. Estimating the accuracy of screening mammography: a metanalysis. Am J Prev Med 1998; 14(2):143-153.

  61. U. S. Department of Health and Human Services. Healthy people 2000: Nacional health promotion and disease preventive objectives. Mild-course review. U.S: Department of Health and Human Services; 1995.

  62. Clover K, Redman S, Forbes J, Sanson Fisher R, Callaghan T. Two sequential randomized trials of community participation to recruit women for mammographic screening. Prev Med 1996;25(2):126-34.




2020     |     www.medigraphic.com